Birdwatch Note
2023-09-25 21:37:47 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Antineoplastons therapy is not FDA-approved, and is not recommended by medical institutions or experts because of a lack of evidence from randomized controlled trials to support its safety or effectiveness in treating cancer. https://www.reuters.com/article/factcheck-antineoplaston-burzynski-cance/fact-check-antineoplastons-not-a-proven-cancer-cure-and-not-an-approved-treatment-idUSL1N34O1TN
Written by F735563C1D6CACAE98B239A5BF3B6B29334E5A32093D655B66C4A4A96408409D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1706412519810879591
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1706422773906559219
- noteId - 1706422773906559219
- participantId -
- noteAuthorParticipantId - F735563C1D6CACAE98B239A5BF3B6B29334E5A32093D655B66C4A4A96408409D Participant Details
- createdAtMillis - 1695677867753
- tweetId - 1706412519810879591
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Antineoplastons therapy is not FDA-approved, and is not recommended by medical institutions or experts because of a lack of evidence from randomized controlled trials to support its safety or effectiveness in treating cancer. https://www.reuters.com/article/factcheck-antineoplaston-burzynski-cance/fact-check-antineoplastons-not-a-proven-cancer-cure-and-not-an-approved-treatment-idUSL1N34O1TN
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-09-25 21:37:47 UTC (1695677867753) |
1969-12-31 23:59:59 UTC (-1) |
2023-09-26 02:11:34 UTC (1695694294267) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-09-25 19:19:36 -0500 | Rating Details | |
| 2023-09-25 19:12:48 -0500 | Rating Details | |
| 2023-09-25 19:06:19 -0500 | Rating Details | |
| 2023-09-25 18:18:25 -0500 | Rating Details | |
| 2023-09-25 17:57:24 -0500 | Rating Details | |
| 2023-09-25 17:55:17 -0500 | Rating Details | |
| 2023-09-25 17:48:50 -0500 | Rating Details | |
| 2023-09-25 17:44:43 -0500 | Rating Details | |
| 2023-09-25 17:43:03 -0500 | Rating Details | |
| 2023-09-25 17:11:25 -0500 | Rating Details | |
| 2023-09-25 17:05:30 -0500 | Rating Details | |
| 2023-09-25 17:01:22 -0500 | Rating Details | |
| 2023-09-25 16:55:58 -0500 | Rating Details | |
| 2023-09-25 16:53:01 -0500 | Rating Details | |
| 2023-09-25 16:48:10 -0500 | Rating Details | |
| 2023-09-26 14:06:52 -0500 | Rating Details | |
| 2023-09-26 12:49:45 -0500 | Rating Details | |
| 2023-09-26 12:45:28 -0500 | Rating Details | |
| 2023-09-26 12:32:27 -0500 | Rating Details | |
| 2023-09-26 07:28:01 -0500 | Rating Details | |
| 2023-09-26 06:08:41 -0500 | Rating Details | |
| 2023-09-26 03:35:45 -0500 | Rating Details | |
| 2023-09-26 01:26:33 -0500 | Rating Details | |
| 2023-09-26 01:12:34 -0500 | Rating Details | |
| 2023-09-26 00:53:48 -0500 | Rating Details | |
| 2023-09-26 00:23:44 -0500 | Rating Details | |
| 2023-09-26 00:15:25 -0500 | Rating Details | |
| 2023-09-25 23:24:48 -0500 | Rating Details | |
| 2023-09-25 22:43:38 -0500 | Rating Details | |
| 2023-09-25 22:25:26 -0500 | Rating Details | |
| 2023-09-25 22:16:46 -0500 | Rating Details | |
| 2023-09-25 21:42:42 -0500 | Rating Details | |
| 2023-09-25 21:35:51 -0500 | Rating Details | |
| 2023-09-25 21:33:24 -0500 | Rating Details | |
| 2023-09-25 21:10:06 -0500 | Rating Details | |
| 2023-09-25 20:31:00 -0500 | Rating Details | |
| 2023-09-25 20:29:16 -0500 | Rating Details | |
| 2023-09-25 20:09:57 -0500 | Rating Details | |
| 2023-09-25 20:08:31 -0500 | Rating Details | |
| 2023-09-25 19:57:46 -0500 | Rating Details | |
| 2023-09-25 19:37:26 -0500 | Rating Details | |
| 2023-09-26 14:19:44 -0500 | Rating Details | |
| 2023-09-26 07:44:10 -0500 | Rating Details | |
| 2023-09-26 05:09:55 -0500 | Rating Details | |
| 2023-09-29 00:05:50 -0500 | Rating Details | |
| 2023-09-26 05:30:27 -0500 | Rating Details | |
| 2023-09-26 01:53:32 -0500 | Rating Details | |
| 2023-11-26 16:34:28 -0600 | Rating Details | |
| 2023-11-23 21:21:00 -0600 | Rating Details |